Surgepays Inc SURG.OQ SURG.O is expected to show a fall in quarterly revenue when it reports results on March 25 for the period ending December 31 2024
The Bartlett Tennessee-based company is expected to report a 74.6% decrease in revenue to $8.223 million from $32.32 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Surgepays Inc is for a loss of 25 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Surgepays Inc is $5.75, above its last closing price of $1.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.24
-0.27
-0.73
Missed
-173.7
Jun. 30 2024
-0.09
-0.07
-0.66
Missed
-842.9
Mar. 31 2024
0.14
0.15
0.07
Missed
-53.3
Dec. 31 2023
0.41
0.41
0.19
Missed
-53.3
Sep. 30 2023
0.28
0.29
0.49
Beat
71.9
Jun. 30 2023
0.15
0.16
0.40
Beat
158.1
Mar. 31 2023
-0.03
-0.03
0.31
Beat
1,133.3
Dec. 31 2022
-0.19
-0.11
0.25
Beat
317.4
This summary was machine generated March 21 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)